Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Soumya Nagaraja

Pediatric Endocrinology Mesa, AZ Medical Doctor

NPI 1316353873 CMS profile 7679956

1450S Dobsonrd,, Ste B221, Mesa, AZ 85202

Open in the dashboard

General payments

$2,240

102 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Soumya Nagaraja of Mesa, AZ is reported in the CMS Open Payments database as having received $2,240 across 102 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $444 18
2024 General $678 26
2023 General $558 23
2022 General $315 22
2021 General $245 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Soumya Nagaraja
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Soumya Nagaraja were reported at $444. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Soumya Nagaraja Pediatric Endocrinology median Middle half National median
2019 $0 $196 $68–$845 $163
2020 $0 $124 $37–$722 $114
2021 $245 $134 $35–$691 $132
2022 $315 $177 $47–$726 $149
2023 $558 $236 $75–$887 $160
2024 $678 $259 $91–$979 $164
2025 $444 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sanofi-Aventis U.S. LLC $318 8 payments
  2. Ascendis Pharma, Inc. $240 10 payments
  3. Tolmar, Inc. $205 10 payments
  4. Rhythm Pharmaceuticals, Inc. $181 8 payments
  5. Dexcom, Inc. $173 8 payments
  6. TOLMAR Pharmaceuticals, Inc. $164 14 payments
  7. Alexion Pharmaceuticals, Inc. $150 6 payments
  8. CutisPharma, Inc. $110 5 payments
  9. Medtronic, Inc. $81 4 payments
  10. Abbott Laboratories $78 3 payments
  11. Other $539 26 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $2,177 93 payments
  2. Education $63 9 payments
Products named General payments · program years 2021–2025
  1. TZIELD $318 8 payments
  2. SKYTROFA $240 10 payments
  3. FENSOLVI Central Precocious Puberty (CPP) $166 8 payments
  4. Imcivree $143 6 payments
  5. Dexcom G6 Transmitter Endocrinology $103 4 payments
  6. STRENSIQ $96 4 payments
  7. TRIPTODUR $95 4 payments
  8. FENSOLVI Hormone Replacement $75 4 payments
  9. DEXCOM G6 TRANSMITTER Endocrinology $71 4 payments
  10. GENOTROPIN $69 4 payments
  11. Other $977 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

102 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Arizona

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record